Formulation and Characterization of Mucoadhesive Patches

Drug delivery systems have evolved significantly over the past few decades, aiming to enhance therapeutic efficacy, improve patient compliance, and minimize side effects (6). Conventional dosage forms such as tablets, capsules, and injections often face challenges including poor bioavailability, rapid drug clearance, and extensive first-pass metabolism. To overcome these limitations, novel drug delivery systems have been developed, among which mucoadhesive drug delivery has emerged as a promising approach (1)(9).

Mucoadhesive systems are designed to adhere to mucosal membranes, such as those in the oral, nasal, ocular, vaginal, and rectal regions (8)(5). This adhesion prolongs the residence time of the drug at the absorption site, enabling sustained and controlled drug release. Additionally, these systems can bypass hepatic first-pass metabolism, thereby improving systemic bioavailability and reducing dosing frequency (4).

Among various mucoadhesive formulations, mucoadhesive patches offer distinct advantages over conventional dosage forms. They are flexible, easy to apply, and capable of delivering both local and systemic therapeutic effects. Compared to gels, ointments, or tablets, patches provide better patient comfort, precise dosing, enhanced stability, and reduced risk of dose dumping. Furthermore, their unidirectional release properties minimize drug loss and optimize therapeutic outcomes.

The objective of this review is to provide a comprehensive overview of the formulation and characterization of mucoadhesive patches. It highlights different polymers employed, methods of preparation, evaluation parameters, advantages, limitations, and recent advances in the field, with emphasis on their potential for future pharmaceutical applications (7)(19).

History and Concept of Mucoadhesion

Definition of Mucoadhesion refers to the phenomenon of adhesion between a polymeric material and the mucosal surface. In pharmaceutical sciences, it is defined as the ability of a synthetic or natural polymer to interact with mucin, thereby increasing the residence time of a drug formulation at the site of application. This property is especially useful in drug delivery systems, as it promotes intimate contact between the dosage form and the absorption site, improving drug bioavailability and therapeutic efficacy (1)(52).

Historical Development

The concept of mucoadhesion emerged in the 1980s as an extension of the broader field of bioadhesion. Initially, bioadhesion was studied in the context of biological cell interactions and wound healing. Later, researchers began applying the principle to drug delivery, recognizing that polymer–mucus interactions could prolong the residence time of dosage forms on mucosal membranes such as the oral cavity, nasal passage, ocular tissue, vaginal wall, and rectal lining. Early formulations focused on gels and ointments, but advancements in polymer science led to the development of more sophisticated systems such as tablets, films, and patches (9)(20). Today, mucoadhesive drug delivery is a well-established area of research, especially for achieving controlled release and bypassing first-pass metabolism (1)(20)(51).

Two stages of mucoadhesion

Mucoadhesion generally occurs in two sequential stages that are useful when designing patches:

1. Contact (or wetting) stage — the formulation comes into intimate contact with the mucosal surface (wetting and spreading of the polymer or patch surface) (1)(20).
2. Consolidation stage — interfacial interactions develop and strengthen (physical and chemical bonding, interpenetration), leading to measurable adhesive strength and residence time. (1)(20)

Figure No 01:- Two stages of mucoadhesion

Theories of Mucoadhesion

Several theories have been proposed to explain the mechanism of mucoadhesion:

1. Wetting Theory – Adhesion occurs when a liquid spreads over a surface, determined by the contact angle and interfacial tension between polymer and mucosa (6).
2. Electronic Theory – Adhesion arises due to electron transfer at the interface of polymer and mucus, leading to the formation of an electrical double layer (6).
3. Adsorption Theory – Involves formation of secondary chemical bonds (van der Waals forces, hydrogen bonding) between polymer chains and mucin glycoproteins (6).
4. Diffusion–Interlocking Theory – Explains adhesion as interpenetration of polymer chains into the glycoprotein network of mucus, creating a semi-permanent bond (20).
5. Fracture Theory – Describes the force required to separate the two surfaces after adhesion has occurred (6).
6. Mechanical Theory – Suggests that adhesion is due to the physical interlocking of polymer into the irregularities of the mucosal surface (1)(7).

Figure No 02:- Theories of Mucoadhesion

Anatomy and Physiology of the Mucosal Membrane

Mucoadhesive drug delivery systems rely on intimate interaction between the dosage form and the mucosal membrane. The human body presents several potential mucosal sites, such as buccal, nasal, vaginal, and rectal mucosa, each with distinct anatomical and physiological characteristics that influence drug absorption and therapeutic outcomes.

1. Buccal Mucosa

The buccal cavity is lined with a stratified squamous epithelium (approximately 500–800 μm thick), beneath which lies a highly vascularized connective tissue. The permeability of the buccal mucosa is higher than that of keratinized epithelium but lower than sublingual mucosa. Its accessibility, large surface area, and avoidance of first-pass metabolism make it an ideal site for mucoadhesive patches aimed at systemic or local drug delivery (8)(3)(52).

Figure No 03:- Buccal Mucosa

2. Nasal Mucosa

The nasal cavity is lined with a ciliated, pseudostratified columnar epithelium rich in blood vessels, with a surface area of about 150–180 cm². The thin epithelial barrier (40–50 μm) and high vascularity enable rapid drug absorption and onset of action. Mucoadhesive patches or films here can bypass gastrointestinal degradation and hepatic metabolism, but mucociliary clearance may limit residence time (3).

3. Vaginal Mucosa

The vaginal mucosa is composed of non-keratinized stratified squamous epithelium (200–300 μm thick) supported by connective tissue and rich in blood vessels. The vaginal route provides a large surface area, avoids hepatic first-pass metabolism, and is particularly useful for local therapy (e.g., antifungal, antibacterial drugs) and systemic delivery (e.g., hormones). Mucoadhesive patches can prolong retention time and improve therapeutic efficacy in this environment (3).

4. Rectal Mucosa

The rectal epithelium is a single layer of columnar epithelial cells with microvilli that increase absorptive capacity. The rectum has a rich blood supply, with partial avoidance of first-pass metabolism depending on the site of absorption (upper vs. lower rectum). Mucoadhesive systems enhance drug contact time with rectal mucosa, improving bioavailability and patient compliance compared to conventional suppositories (3).

Formulation of Mucoadhesive Patches

The successful design of mucoadhesive patches requires the careful selection of polymers, active pharmaceutical ingredients (APIs), excipients, and preparation techniques. Each component plays a critical role in determining the bioadhesive strength, drug release profile, mechanical properties, and therapeutic efficiency of the final dosage form.

1. Polymers Used

Polymers are the backbone of mucoadhesive patches, imparting adhesion, mechanical strength, and controlled release. They are broadly classified as:

• Natural Polymers: Chitosan, sodium alginate, pectin, guar gum, xanthan gum. Advantages: biocompatible, biodegradable, non-toxic. Limitation: batch variability.
• Semi-synthetic Polymers: Hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), methylcellulose, sodium carboxymethyl cellulose. Advantages: better swelling and flexibility.
• Synthetic Polymers: Polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), carbopol, polyethylene oxide (PEO), Eudragit®. Advantages: high reproducibility, good mechanical strength.

Often, polymer blends are used to balance adhesion, flexibility, and controlled drug release (7)(19).

2. Active Pharmaceutical Ingredients (APIs)

A wide range of APIs can be incorporated into mucoadhesive patches for local or systemic action:

• Analgesics: Lidocaine, diclofenac.
• Antifungals/Antibacterials: Clotrimazole, miconazole, metronidazole.
• Cardiovascular drugs: Propranolol, captopril, nifedipine.
• Hormones: Estradiol, progesterone, testosterone.
• Other systemic drugs: Ondansetron, insulin, nicotine, buprenorphine.

The choice of drug depends on molecular weight, solubility, dose requirement, and intended therapeutic effect (4).

3. Excipients in Mucoadhesive Patches

• Plasticizers: Glycerol, propylene glycol, polyethylene glycol (PEG), dibutyl phthalate – improve flexibility, elasticity, and prevent brittleness.
• Permeation Enhancers: Dimethyl sulfoxide (DMSO), oleic acid, menthol, bile salts – increase drug permeability across mucosal membranes.
• Solvents: Water, ethanol, isopropanol, chloroform – aid in dissolving polymers and APIs during formulation.
• Other additives: Sweeteners (sorbitol, mannitol), flavoring agents (peppermint oil, vanillin), and coloring agents for patient acceptability (10)(12).

Methods of Preparation of Mucoadhesive Patches

Mucoadhesive patches can be prepared by various techniques depending on the type of polymer, drug properties, and desired drug release profile. The most commonly used methods are:

1. Solvent Casting Method

Process:

• Dissolve the selected polymer(s) in a suitable solvent (water, ethanol, or a mixture).
• Add plasticizers (e.g., glycerol, PEG) to improve flexibility.
• Disperse or dissolve the drug uniformly in the polymer solution.
• Pour the solution onto a flat surface such as a Petri dish or Teflon-coated mold.
• Allow the solvent to evaporate at controlled temperature, forming a uniform thin film.
• Peel off the dried film and cut into patches of desired size

Figure No 04:- Solvent Casting Method

Figure No 05:- Hot-Melt Extrusion (HME)

Figure No 06:- Franz Diffusion Cell Method

• 5. Ex-vivo and In-vivo Studies
• Ex-vivo Studies:
  • Use excised animal mucosa to study drug permeation and mucoadhesion under simulated physiological conditions.
  • Provides data on bioadhesion, swelling, and drug diffusion before in-vivo studies.
• In-vivo Studies:
  • Conducted in animal models or human volunteers to evaluate bioavailability, residence time, therapeutic effect, and safety.
  • Parameters include plasma drug concentration (pharmacokinetics), irritation testing, and local tissue compatibility.
  • Non-invasive imaging or labeling techniques may be used to track patch retention and drug release in real time (16).

Applications of Mucoadhesive Patches

Mucoadhesive patches have emerged as versatile drug delivery systems due to their ability to adhere to mucosal surfaces, prolong residence time, and provide controlled drug release. Their applications span systemic, local, and targeted therapy depending on the site of application.

1. Buccal Delivery

• Overview:
  The buccal mucosa is a highly vascularized tissue suitable for systemic drug delivery, bypassing first-pass metabolism and reducing gastrointestinal degradation.
• Applications:
  • Peptides and Proteins: Insulin, calcitonin, and other peptide drugs are delivered via buccal patches to improve bioavailability, as they are otherwise degraded in the GI tract.
  • Cardiovascular Drugs: Propranolol, nitroglycerin, and captopril patches enable sustained plasma levels for chronic management of hypertension and angina.
  • Analgesics/Antipyretics: Buccal patches containing lidocaine or diclofenac provide rapid pain relief and local action.
• Advantages:
  • Non-invasive and patient-friendly.
  • Enables controlled or sustained release.
  • Reduces dosing frequency and improves compliance (8)(4).

2. Periodontal Patches

• Overview: Designed specifically for the treatment of periodontal diseases, these patches are applied directly into periodontal pockets.
• Applications:
  • Delivery of antibiotics such as tetracycline, doxycycline, or metronidazole for localized therapy.
  • Anti-inflammatory drugs to manage gingivitis or periodontitis.
• Advantages:
  • Maintains high local drug concentration without systemic exposure.
  • Reduces side effects associated with oral administration of antibiotics.
  • Prolonged retention in the periodontal pocket ensures sustained drug action (5)(51).

3. Vaginal and Rectal Patches

• Vaginal Patches:
  • Used for local therapy (antifungal, antibacterial, or contraceptive agents) and systemic delivery (hormones like estradiol and progesterone).
  • Prolonged retention due to mucoadhesion ensures controlled release and improved efficacy.
  • Reduces dosing frequency and enhances patient comfort.
• Rectal Patches:
  • Administered for local treatment (hemorrhoids, infections) or systemic delivery of drugs like antiemetics or cardiovascular agents.
  • Partially avoids hepatic first-pass metabolism depending on site of absorption.
• Advantages of Vaginal/Rectal Patches:
  • Improved drug bioavailability.
  • Targeted and sustained drug release.
  • Minimally invasive and well-tolerated (17).

4. Targeted Drug Delivery

• Overview: Mucoadhesive patches are increasingly being explored for site-specific and targeted delivery in various therapeutic areas.
• Examples:
  • Cancer Therapy: Buccal or vaginal patches delivering chemotherapeutic agents directly to tumor sites to minimize systemic toxicity.
  • Antiviral Therapy: Delivery of drugs like acyclovir to oral or genital mucosa for localized antiviral effect.
  • Hormone Replacement: Targeted delivery via vaginal patches ensures steady systemic absorption with minimal fluctuations.
• Advantages:
  • Localized therapy reduces systemic side effects.
  • Controlled release improves therapeutic outcomes.
  • Potential for personalized medicine based on patient-specific requirements (18)(34)(35).

Advantages of Mucoadhesive Patches

1. Improved Patient Compliance
   • Patches are non-invasive, easy to apply, and discreet.
   • Eliminate the need for frequent dosing, improving adherence, especially in chronic therapy.
   • Taste-masking and minimal interference with daily activities enhance patient acceptability.
2. Bypass of First-Pass Metabolism
   • Drugs delivered via mucosal routes (buccal, nasal, vaginal, rectal) bypass hepatic first-pass metabolism.
   • Increases systemic bioavailability for drugs that are extensively metabolized in the liver when administered orally.
3. Sustained and Controlled Release
   • Polymers in the patch matrix allow prolonged drug release over several hours.
   • Maintains steady plasma drug concentrations, reducing peak-trough fluctuations.
   • Useful for drugs with short half-lives or those requiring continuous therapeutic levels.
4. Localized Therapy
   • Targeted delivery at the site of action reduces systemic exposure.
   • Minimizes side effects while improving therapeutic outcomes, e.g., periodontal or vaginal patches.
5. Flexibility in Formulation
   • Compatible with a wide range of drugs: peptides, hormones, analgesics, antivirals, and antimicrobials.
   • Can incorporate excipients like plasticizers, permeation enhancers, and flavoring agents to improve efficacy and patient acceptability (1)(5)(9).

Limitations of Mucoadhesive Patches

1. Potential for Mucosal Irritation
   • Some polymers or permeation enhancers may cause local irritation or discomfort.
   • Surface pH mismatch or prolonged adhesion may lead to redness, burning, or ulceration.
2. Limited Drug Load
   • The small size and thin nature of patches restrict the amount of drug that can be incorporated.
   • High-dose drugs may not be feasible for this delivery system.
3. Limited Absorption Area
   • Mucosal surfaces have a limited surface area (e.g., buccal cavity ~50 cm²).
   • Only drugs that can be absorbed in small quantities or are potent at low doses are suitable.
4. Variability in Adhesion and Retention
   • Factors like saliva, mucosal turnover, or patient movement may reduce residence time.
   • Adhesion strength must be carefully optimized for consistent therapeutic effect.
5. Formulation Complexity and Stability
   • Requires careful selection of polymers and excipients to balance adhesion, drug release, and mechanical properties.
   • Storage and packaging must prevent patch drying, brittleness, or degradation.

Recent Advances and Future Prospects

The field of mucoadhesive patches is evolving rapidly due to innovations in polymer science, nanotechnology, and personalized medicine. These advancements aim to overcome the limitations of conventional patches, enhance drug bioavailability, and enable targeted, patient-specific therapy.

1. Nanotechnology-Based Mucoadhesive Patches

• Overview: Incorporation of nanocarriers such as nanoparticles, nanofibers, liposomes, and solid lipid nanoparticles into mucoadhesive patches has revolutionized drug delivery.
• Advantages:
  • Enhanced Drug Solubility: Nanocarriers improve the solubility of poorly water-soluble drugs.
  • Controlled and Sustained Release: Nanoparticles within the polymer matrix allow precise modulation of drug release kinetics.
  • Improved Permeation: Nanosized drug carriers can penetrate the mucosal layer more efficiently.
  • Targeted Therapy: Functionalized nanoparticles can deliver drugs selectively to specific tissues or cells.
• Applications: Delivery of peptides, anticancer drugs, antivirals, and vaccines through buccal, nasal, or vaginal routes (18)(13).

2. Combination with Permeation Enhancers

• Overview: Permeation enhancers are substances that transiently increase mucosal membrane permeability to improve drug absorption.
• Common Enhancers: Fatty acids (oleic acid), surfactants (sodium lauryl sulfate), bile salts, cyclodextrins, and menthol.
• Advantages:
  • Facilitate the delivery of high molecular weight drugs (e.g., peptides, proteins) across mucosa.
  • Improve systemic bioavailability while maintaining patch adhesion and integrity.
• Considerations: Selection of safe and biocompatible enhancers is crucial to avoid mucosal irritation or long-term toxicity.

3. Personalized Medicine Approaches

• Overview: Advances in 3D printing, microfabrication, and computational modeling allow the development of customized mucoadhesive patches tailored to individual patient needs.
• Advantages:
  • Patient-Specific Dosage: Precise control of drug content and release rate based on patient age, weight, or disease state.
  • Customized Shape and Size: Patches can be designed for difficult-to-access mucosal sites or pediatric/geriatric populations.
  • Combination Therapy: Multiple drugs can be incorporated in a single patch with controlled release profiles (16).
• Future Prospects: Integration of biosensors or stimuli-responsive polymers may enable “smart patches” that release drugs in response to physiological signals (pH, temperature, or enzymatic activity) (16).

CONCLUSION

Mucoadhesive patches have emerged as a versatile and promising drug delivery platform, offering advantages over conventional dosage forms such as enhanced patient compliance, bypass of first-pass metabolism, sustained drug release, and targeted/localized therapy. This review highlights the key findings in the field, including:

1. Formulation Strategies: A variety of natural, semi-synthetic, and synthetic polymers are used to achieve desired adhesion, flexibility, and controlled drug release. Plasticizers, permeation enhancers, and suitable solvents are critical excipients, while methods like solvent casting, hot-melt extrusion, direct compression, lyophilization, electrospinning, and 3D printing allow customization of patch properties.
2. Evaluation Parameters: Comprehensive characterization—including physicochemical tests (thickness, weight variation, folding endurance), mucoadhesive strength, swelling behavior, surface pH, in-vitro drug release, and ex-vivo/in-vivo studies—is essential for ensuring patch quality, efficacy, and safety.
3. Applications: Mucoadhesive patches have wide-ranging applications for systemic delivery (e.g., peptides, cardiovascular drugs), localized therapy (e.g., periodontal, vaginal, rectal), and targeted drug delivery, demonstrating their potential across multiple therapeutic areas.
4. Recent Advances: Innovations such as nanotechnology-based patches, combination with permeation enhancers, and personalized medicine approaches are expanding the scope of mucoadhesive drug delivery, enabling controlled, targeted, and patient-specific therapies.

Research Gaps:

• Limited drug loading capacity restricts use for high-dose drugs.
• Potential mucosal irritation and variability in adhesion remain challenges.
• Long-term stability and clinical translation of advanced patches (e.g., nanotechnology-based or 3D-printed patches) need further study.
• More in-vivo studies and clinical trials are required to establish safety, efficacy, and regulatory approval.

Potential Future Trends:

• Development of smart mucoadhesive patches capable of on-demand, stimulus-responsive drug release.
• Integration of biosensors for real-time monitoring of therapeutic outcomes.
• Exploration of multidrug patches for combination therapy.
• Expansion of personalized, patient-centric patch designs using 3D printing and advanced polymer engineering.

In summary, mucoadhesive patches represent a promising platform for innovative, effective, and patient-friendly drug delivery, with considerable scope for future research and clinical application.

REFERENCES

1. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556–1568. doi:10.1016/j.addr.2005.06.002
2. Park K. Controlled Drug Delivery: Challenges and Strategies. 2nd ed. New York: American Chemical Society; 2014.
3. Squier CA, Wertz PW. Structure and function of the oral mucosa and implications for drug delivery. Adv Drug Deliv Rev. 1996;19:3–22. doi:10.1016/0169-409X (96)00020-6
4. Rathbone MJ, Drummond BK, Tucker IG. Oral mucosal drug delivery. Adv Drug Deliv Rev. 1994;13:43–84. doi:10.1016/0169-409X (94)90002-4
5. Khanna R, Agarwal SP. Mucoadhesive drug delivery systems: Recent advances and applications. Drug Deliv. 2013;20(6):1–10. doi:10.3109/10717544.2013.841000
6. Chien YW, Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker; 1992.
7. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27–46. doi:10.1016/S0939-6411(00)00082-9
8. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Sci. 1998;1(1):15–30.
9. Soppimath KS, Kulkarni AR, Rudzinski WE. Mucoadhesive drug delivery systems: Strategies and applications. Crit Rev Ther Drug Carrier Syst. 2001;18(6):553–580. doi:10.1615/CritRevTherDrugCarrierSyst.v18.i6.20
10. Gupta P, Vermani K, Garg S. Hydrogels: From controlled release to pH-responsive drug delivery. Drug Discov Today. 2002;7(10):569–579. doi:10.1016/S1359-6446(02)02344-1
11. Rathbone MJ, Hadgraft J, Roberts MS. Modified-Release Drug Delivery Technology. 2nd ed. New York: Marcel Dekker; 2003.
12. Bala R, Pawar P, Khanna S, Arora S. Multiparticulate drug delivery systems for controlled release. Expert Opin Drug Deliv. 2006;3(1):1–15. doi:10.1517/17425247.3.1.1
13. Pandey S, Khuller GK. Liposomes as drug carriers: An overview. Indian J Exp Biol. 2000;38:289–297.
14. Choudhury H, et al. Mucoadhesive films for drug delivery: Formulation and evaluation. Int J Pharm Sci Rev Res. 2013;22(1):112–119.
15. Boateng JS, Matthews KH, Stevens HN, Eccleston GM. Wound healing dressings and drug delivery systems: A review. J Pharm Sci. 2008;97(8):2892–2923. doi:10.1002/jps.21210
16. Bala R, Pawar P, Khanna S, Arora S. Recent advances in mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 2013;39(3):443–452. doi:10.3109/03639045.2012.684377
17. Srikumar K, et al. Advances in mucoadhesive drug delivery systems: Current status and future prospects. Int J Pharm Sci Rev Res. 2014;27(2):112–119.
18. Zhang Z, Feng SS. Nanoparticles and nanostructures for oral and buccal drug delivery. Adv Drug Deliv Rev. 2006;58:515–528. doi:10.1016/j.addr.2006.03.001
19. Chavanpatil MD, et al. Mucoadhesive polymeric platforms for controlled drug delivery. Drug Dev Ind Pharm. 2006;32(9):1019–1035. doi:10.1080/03639040600752369
20. Peppas NA, Sahlin JJ. Hydrogels as mucoadhesive and drug delivery systems. J Control Release. 1996;43(1):75–86. doi:10.1016/0168-3659(96)00018-4
21. Sharma, K., & Garg, R. (2015). A review on mucoadhesive drug delivery system. International Journal of Pharmaceutical Sciences and Research, 6(5), 1888–1904.
22.  Renggli, K., & Allemann, E. (2016). Mucoadhesive drug delivery systems: Focus on novel approaches. Expert Opinion on Drug Delivery, 13(2), 295–311.
23.  Ghasemzadeh, M., & Papi, A. (2016). Mucoadhesive polymers: An overview. Journal of Applied Polymer Science, 133(47).
24.  Alopaeus, L., & Stjärnkvist, C. (2017). Recent progress in mucoadhesive buccal films. Journal of Drug Delivery Science and Technology, 39, 268–275.
25. Vora, C., & Jadav, P. (2017). A review on recent advances in mucoadhesive drug delivery systems. International Journal of Research in Pharmaceutical Sciences, 8(3), 299–306.
26.  Singh, J., & Tripathi, M. (2018). Mucoadhesive drug delivery systems for local and systemic action: A review. Asian Journal of Pharmaceutical and Clinical Research, 11(4), 1–7.
27.  Saini, G., & Kumar, S. (2018). Mucoadhesive buccal films: An overview of fabrication methods and characterization techniques. International Journal of Pharmaceutical Sciences and Research, 9(8), 3097–3108.
28.  Irfan, M., & Farooq, U. (2019). Development and evaluation of mucoadhesive buccal films of an anti-inflammatory drug. Journal of Pharmaceutical Investigation, 49(5), 519–531.
29.  Shirvan, A. R., Bashari, A., & Hemmatinejad, N. (2019). New insight into the fabrication of smart mucoadhesive buccal patches as a novel controlled-drug delivery system. European Polymer Journal, 119, 541–550.
30. Budhrani, A. B., et al. (2020). Buccal drug delivery system: A review. American Journal of PharmTech Research, 10(2), 274–285.
31. Jha, S., & Shahi, P. (2020). Mucoadhesive drug delivery systems: Current developments and future perspectives. Journal of Drug Delivery and Therapeutics, 10(2), 177–187.
32.  Narayana, S. N., & Manjula, M. (2020). Recent advances in buccal drug delivery systems: A review. International Journal of Pharmaceutical Sciences Review and Research, 63(1), 108–114.
33.  Alawdi, S., & Solanki, A. B. (2021). Mucoadhesive Drug Delivery Systems: A Review of Recent Developments. Journal of Scientific Research in Medical and Biological Sciences, 2(1), 50–64.
34.  Goud, T. M., & Kumar, A. (2021). Nano-formulations for mucoadhesive drug delivery: A review. Current Drug Delivery, 18(9), 1279–1296.
35. Garg, A., & Singh, J. (2021). Nanotechnology-based mucoadhesive delivery systems: Trends and applications. Drug Delivery and Translational Research, 11(4), 1641–1660.
36.  Yermak, I. M., Davydova, V. N., & Volod'ko, A. V. (2022). Mucoadhesive Marine Polysaccharides. Marine Drugs, 20(8), 522.
37. Bhatiya, S., & Sharma, D. (2022). Nanoparticles Loaded Mucoadhesive Buccal Patches - Review. Journal of Pharmaceutical Research International, 34(46B), 31–41.
38. Russo, E., et al. (2022). Bio-Inspired Muco-Adhesive Polymers for Drug Delivery Applications. Polymers, 14(24), 5459.
39. 39 Rajendran, J., & Narayanan, J. (2022). Recent advances in oral mucoadhesive drug delivery. Journal of Pharmacy and Pharmaceutical Sciences, 25, 367–381.
40. Singh, A., et al. (2023). Review on buccal drug delivery system. International Journal of Novel Research and Development, 8(10), 1–15.
41. Sahoo, B., et al. (2023). Recent advances in mucoadhesive delivery systems: A focus on polymers and applications. International Journal of Research in Pharmaceutical Sciences, 14(3), 856–864.
42. Grewal, A., & Goyal, A. (2023). Formulation and evaluation of mucoadhesive buccal films: A novel approach for pain management. International Journal of Pharmaceutical Sciences and Drug Research, 15(2), 136–143.
43. V. V., Prasanth, et al. (2011). Buccal tablet-as buccal drug delivery: an overview. Journal of Pharmacy Research, 4(3), 706–709.
44. Srivastava, M., et al. (2015). Current status of buccal drug delivery system: a review. Journal of Drug Delivery & Therapeutics, 5(1), 34–40.
45.  Koirala, B., & Shah, M. (2019). Mucoadhesive drug delivery systems: Fundamentals, recent advances and pharmaceutical applications. International Journal of Pharmaceutical Sciences Review and Research, 54(1), 1–12.
46. Dodiya, B., & Baria, A. (2021). Advances in Mucoadhesive Drug Delivery System: Enhancing Efficacy and Patient Compliance. Journal of Drug Delivery and Therapeutics, 11(3-S), 116–123.
47.  Khan, S., & Garg, R. (2022). Mucoadhesive buccal films: A review on the use of natural polymers. International Journal of Research in Pharmaceutical Sciences, 13(2), 1957–1964.
48.  Kumar, N., et al. (2023). Recent advancement in mucoadhesive buccal patch for drug delivery. Journal of Pharmaceutical Research International, 35(29), 83–94.
49. Koli, K., et al. (2024). Recent advances in biopolymer-based mucoadhesive drug delivery systems for oral application. Journal of Drug Delivery Science and Technology, 91, 105227.
50.  Singh, S., et al. (2024). Oral mucoadhesive drug delivery system: Formulation strategies and evaluation techniques. World Journal of Advanced Research and Reviews, 24(01), 1706–1719.
51. Ghosalkar AR, Shettigar R, Phalak S. Buccal mucoadhesive tablets: A comprehensive review on formulation, mechanism, and clinical applications. International Journal of Scientific Research in Science and Technology. 2025;12.
52. Janvalkar, M., Shettigar, R., & Phalak, S. (2025). Advancements in topical oro-mucoadhesive gel formulations for aphthous ulcers: Innovations in bio-adhesion, drug delivery and therapeutic outcomes. International Journal of Pharmaceutical Research and Development, 7(1), 319–329.